Agomelatine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Agomelatine.svg | |
| Agomelatine
| |
| Systematic (IUPAC) name | |
| N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| Chemical data | |
| Formula | C15H17NO2 |
| Mol. mass | 243.301 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 1 to 2 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Agomelatine (Valdoxan®, Melitor®) is chemical compound that is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression (forced swimming test in rodents). It is concluded that the antidepressant-like activity in this model most probably involves a combination of both its melatonin agonist and 5-HT(2C) receptor antagonist properties.
Controlled studies with humans have shown that agomelatine is comparable to paroxetine in treatment of major depression. Agomelatine showed significant benefits over paroxetine due to the complete absence of side effects including the associated sexual side effects that are troublesome with some antidepressants. Because of its actions upon the melatonin receptors, agomelatine shows a marked improvement in sleep quality. However unlike other antidepressants with sedative effects there were no associated instances of daytime drowsiness.
On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. The CHMP had no special concerns about the side effects.
According to the pipeline page on Novartis.com, the company plans to file agomelatine (AGO178) in 2008. [1]
References
External links
- Novartis pipeline
- Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist
- Remitted Depressed Patients Experience Less Sexual Dysfunction with Agomelatine (Valdoxan) than with Venlafaxine XR (Effexor XR): Presented at CPA
- Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors
- The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways
- Agomelatine treatment has promising results in transgenic murine modelde:Agomelatin
